[go: up one dir, main page]

WO2021062048A3 - Methods and systems for modulating hepatic gaba production or release to alter food intake in monogastric species - Google Patents

Methods and systems for modulating hepatic gaba production or release to alter food intake in monogastric species Download PDF

Info

Publication number
WO2021062048A3
WO2021062048A3 PCT/US2020/052571 US2020052571W WO2021062048A3 WO 2021062048 A3 WO2021062048 A3 WO 2021062048A3 US 2020052571 W US2020052571 W US 2020052571W WO 2021062048 A3 WO2021062048 A3 WO 2021062048A3
Authority
WO
WIPO (PCT)
Prior art keywords
gaba
food intake
methods
activity
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/052571
Other languages
French (fr)
Other versions
WO2021062048A2 (en
Inventor
Benjamin J. RENQUIST
Caroline E. GEISLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arizona
Original Assignee
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arizona filed Critical University of Arizona
Publication of WO2021062048A2 publication Critical patent/WO2021062048A2/en
Priority to PCT/US2021/025629 priority Critical patent/WO2021203033A2/en
Publication of WO2021062048A3 publication Critical patent/WO2021062048A3/en
Anticipated expiration legal-status Critical
Priority to US17/937,604 priority patent/US20230128194A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Methods and compositions (such as compounds, drugs, molecules, etc,) for modulating food intake, e.g., increasing food intake or reducing food intake, in a monogastric animal species. Certain methods herein feature administering to the animal a composition that depresses hepatic GABA production, depresses GABA release, inhibits expression or activity of GABA transaminase, inhibits expression or activity of particular GABA transporters associated with export of GABA, increases expression or activity of particular GABA transporters associated with GABA re- uptake, etc. The methods may help decrease food intake and subsequently improve weight loss. Certain methods herein may feature administering to the animal a composition that activates hepatic GABA production, activates GABA release, increases expression or activity of GABA transaminase, increases expression or activity of particular GABA transporters associated with export of GABA, decreases expression or activity of particular GABA transporters associated with GABA re-uptake, etc. The methods may help increase food intake, and subsequently help promote weight gain.
PCT/US2020/052571 2017-05-26 2020-09-24 Methods and systems for modulating hepatic gaba production or release to alter food intake in monogastric species Ceased WO2021062048A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/US2021/025629 WO2021203033A2 (en) 2020-04-02 2021-04-02 Methods and compositions to alter hepatic gaba release to treat obesity-related conditions
US17/937,604 US20230128194A1 (en) 2017-05-26 2022-10-03 Methods and compositions to alter hepatic gaba release to treat obesity-related conditions

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962905135P 2019-09-24 2019-09-24
US62/905,135 2019-09-24
US201916617108A 2019-11-26 2019-11-26
US16/617,108 2019-11-26
US202063004373P 2020-04-02 2020-04-02
US63/004,373 2020-04-02

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2018/034680 Continuation-In-Part WO2018218161A2 (en) 2017-05-26 2018-05-25 Methods and compositions for regulating glucose homeostasis
US16/617,108 Continuation-In-Part US20200163908A1 (en) 2017-05-26 2018-05-25 Methods and compositions for regulating glucose homeostasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/025629 Continuation-In-Part WO2021203033A2 (en) 2017-05-26 2021-04-02 Methods and compositions to alter hepatic gaba release to treat obesity-related conditions

Publications (2)

Publication Number Publication Date
WO2021062048A2 WO2021062048A2 (en) 2021-04-01
WO2021062048A3 true WO2021062048A3 (en) 2021-06-03

Family

ID=75166821

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/052571 Ceased WO2021062048A2 (en) 2017-05-26 2020-09-24 Methods and systems for modulating hepatic gaba production or release to alter food intake in monogastric species

Country Status (1)

Country Link
WO (1) WO2021062048A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114774338B (en) * 2022-03-29 2023-08-08 北京航空航天大学 Probiotics for producing butyric acid, construction method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018218161A2 (en) * 2017-05-26 2018-11-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for regulating glucose homeostasis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018218161A2 (en) * 2017-05-26 2018-11-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for regulating glucose homeostasis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAKEHASHI, A ET AL.: "Valerian Inhibits Rat Hepatocarcinogenesis by Activating GABA(A) Receptor-Mediated Signaling", PLOS ONE, vol. 9, no. 11, 24 November 2014 (2014-11-24), pages 1 - 21, XP055829681, DOI: 10.1371/journal.pone.0113610 *
ROH, YS ET AL.: "G-Aminobutyric acid promotes methionine-choline deficient diet-induced nonalcoholic steatohepatitis", THE JOURNAL OF BIOMEDICAL RESEARCH, vol. 31, no. 1, 2017, pages 65 - 73, XP055829680, DOI: 10.7555/JBR.31.2016K0007 *

Also Published As

Publication number Publication date
WO2021062048A2 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
MX2016006147A (en) A feed supplement and a feed composition comprising resin acid based composition.
MX2018012553A (en) METHODS TO IMPROVE CORRAL BIRD AGRICULTURAL PRODUCTION THROUGH THE ADMINISTRATION OF MICROBIAL CONSORTS OR PURIFIED VINTAGES OF THE SAME.
MX392115B (en) COMPOSITIONS INCLUDING CHOLINE.
BR112018009235A8 (en) food additive composition
EA201170954A1 (en) PHARMACEUTICAL OR FOOD COMPOSITION WITH CONTROLLED DELIVERY AND METHOD FOR ITS PREPARATION
BR112016029894A2 (en) method for increasing weight gain and / or improving the feed ratio of farm animals, and using one or more protolytic enzymes in combination with at least one phytase in the feed.
PH12014500590A1 (en) Antimicrobial formulations with pelargonic acid
WO2015109362A3 (en) Method for reducing total gas production and/or methane production in a ruminant animal
WO2020160187A3 (en) Compositions and methods for producing food products with recombinant animal protein
BRPI0913063A8 (en) USE OF AN ACYLAMINOACID COMPOUND OR A SALT THEREOF TO GENERATE A MAINLY SPICY AND NON-BURNING SENSATION IN A FOOD PREPARATION, AND FOOD PREPARATION COMPRISING SAID COMPOUND
AU2018280875A1 (en) Solid compositions for oral administration
MX2014004507A (en) Novel coating system.
WO2019241584A8 (en) Composition for supporting animal with cancer
WO2018191482A3 (en) Methods of treating developmental encephalopathies
WO2022218941A3 (en) Compositions and methods for inhibiting ketohexokinase (khk)
BR112012022209A2 (en) pharmaceutical compositions comprising monoterpenes
ECSP13012702A (en) FOOD PRODUCTS THAT INCLUDE HYDROLYZED INTEGRAL GRAIN
WO2021062048A3 (en) Methods and systems for modulating hepatic gaba production or release to alter food intake in monogastric species
MX2020001574A (en) Systems and methods for the control of acute hepatopancreatic necrosis disease.
BR112019002545A2 (en) lactobacillus salivarius, composition for animal feed additives, animal feed and method for preparing lactobacillus salivarius
BR112014000721A2 (en) Method of Using Activated Functional Proteins to Improve Animal Health
SG179131A1 (en) Modified erythropoietin to which water-soluble long-chain molecule is added
BR112014032478A2 (en) nanogel comprising water-soluble active ingredients
PH12015502037A1 (en) Activating adiponectin by casein hydrolysate
FR2981246B1 (en) USEFUL FOOD PRODUCT AS NUTRITIONAL SUPPLEMENT OR COMPLETE MEAL

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20867768

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20867768

Country of ref document: EP

Kind code of ref document: A2